Top

Published in:

Open Access 01-12-2024 | Analysis

New direction: identification of immunoinflammatory subtypes and potential therapeutic targets for cholangiocarcinoma

Authors: Zhixuan Chen, Honghu Song, Junrui Tang, Jiao Liu, Lina Xia

Published in: Discover Oncology | Issue 1/2024

Abstract

Background

Cholangiocarcinoma (CHOL) is a rare cancer with low survival rates. Despite advances in precision medicine targeting molecular subtypes, the immune subtypes of CHOL remain poorly understood. This study aimed to identify immune subtypes of CHOL and investigate their implications in the metabolic regulation of macrophage functions in inflammation.

Methods

We conducted a comprehensive analysis of transcriptome and single-cell sequencing data from multiple databases to classify the immune subtypes of CHOL. Immune cell infiltration within the tumor microenvironment (TME) and the metabolic pathways involved in macrophage activation and polarization were also analyzed.

Results

Two distinct immune subtypes, immune-infiltrated CS1 and immune-depleted CS2, were identified in CHOL. CS1 exhibited a highly active TME with substantial immune cell infiltration, including macrophages, and activation of immune-related signaling pathways, such as inflammatory and interferon pathways. In contrast, CS2 was characterized by a deficiency in immune components and poorer prognosis. Metabolic regulation of macrophages, particularly the downregulation of oxidative phosphorylation in CS1, suggested a shift towards glycolysis as an energy source for activated macrophages, contributing to the immune-responsive phenotype observed in CS1. Additionally, the oncogenic role of DLX5 in CHOL was revealed, with potential impacts on macrophage functions in inflammation.

Conclusion

This study provides insights into immune subtype classification, novel biomarker identification, and the metabolic regulation of macrophage functions in CHOL. Understanding macrophage metabolic reprogramming within immune subtypes may contribute to the development of targeted immunotherapies for CHOL.

Available only for authorised users

Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer. 2016;122(9):1349–69. https://doi.org/10.1002/cncr.29692.CrossRefPubMed

Abdel-Rahman O, Elsayed Z, Elhalawani H. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane Database Syst Rev. 2018. https://doi.org/10.1002/14651858.CD011746.pub2.CrossRefPubMedPubMedCentral

Ilyas SI, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95–111. https://doi.org/10.1038/nrclinonc.2017.157.CrossRefPubMed

Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8(9):512–22. https://doi.org/10.1038/nrgastro.2011.131.CrossRefPubMedPubMedCentral

Patel T. Cholangiocarcinoma-controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8(4):189–200. https://doi.org/10.1038/nrgastro.2011.20.CrossRefPubMedPubMedCentral

Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24(2):115–25. https://doi.org/10.1055/s-2004-828889.CrossRefPubMed

Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31(9):1188–95. https://doi.org/10.1200/jco.2012.41.5984.CrossRefPubMed

Xie D, Kuang Y, Yuan B, et al. Convenient and highly efficient adsorption of diosmetin from lemon peel by magnetic surface molecularly imprinted polymers. J Mater Sci Technol. 2025;211:159–70. https://doi.org/10.1016/j.jmst.2024.06.001.CrossRef

Li Y, Shimizu S, Mizumoto M, et al. Proton beam therapy for multifocal hepatocellular carcinoma (hcc) showing complete response in pathological anatomy after liver transplantation. Cureus. 2022;14(6):e25744. https://doi.org/10.7759/cureus.25744.CrossRefPubMedPubMedCentral

10.

Li Y, Mizumoto M, Oshiro Y, et al. A retrospective study of renal growth changes after proton beam therapy for pediatric malignant tumor. Curr Oncol. 2023;30(2):1560–70. https://doi.org/10.3390/curroncol30020120.CrossRefPubMedPubMedCentral

11.

Wu S, Zhao K, Wang J, et al. Recent advances of tanshinone in regulating autophagy for medicinal research. Front Pharmacol. 2022;13:1059360. https://doi.org/10.3389/fphar.2022.1059360.CrossRefPubMed

12.

Long H, Ryu S, Zheng X-L, Zhang L-S, Li L-Y, Zhang Z-S. Peptide L1H9 derived from the interaction of structural human rhomboid family 1 and 80-kDa subunit of Ku antigen sensitizes breast cancer to chemoradiotherapy. Adv Compos Hybrid Mater. 2023. https://doi.org/10.1007/s42114-023-00784-4.CrossRef

13.

Zhao S, Yue G, Liu X, et al. Lignin-based carbon quantum dots with high fluorescence performance prepared by supercritical catalysis and solvothermal treatment for tumor-targeted labeling. Adv Compos Hybrid Mater. 2023. https://doi.org/10.1007/s42114-023-00645-0.CrossRef

14.

Zhang J, Zhang B, Pu C, et al. Nanoliposomal Bcl-xL proteolysis-targeting chimera enhances anti-cancer effects on cervical and breast cancer without on-target toxicities. Adv Compos Hybrid Mater. 2023. https://doi.org/10.1007/s42114-023-00649-w.CrossRefPubMedPubMedCentral

15.

Ding S, Chen X, Shen K. Single-cell RNA sequencing in breast cancer: understanding tumor heterogeneity and paving roads to individualized therapy. Cancer Commun. 2020;40(8):329–44. https://doi.org/10.1002/cac2.12078.CrossRef

16.

Röcken C. Molecular classification of gastric cancer. Expert Rev Mol Diagn. 2017;17(3):293–301. https://doi.org/10.1080/14737159.2017.1286985.CrossRefPubMed

17.

McConkey DJ, Choi W. Molecular subtypes of bladder cancer. Curr Oncol Rep. 2018;20(10):77. https://doi.org/10.1007/s11912-018-0727-5.CrossRefPubMed

18.

Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019;16(4):207–20. https://doi.org/10.1038/s41575-019-0109-y.CrossRefPubMed

19.

Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482–92. https://doi.org/10.1093/annonc/mdw168.CrossRefPubMed

20.

Jeschke J, Bizet M, Desmedt C, et al. DNA methylation-based immune response signature improves patient diagnosis in multiple cancers. J Clin Invest. 2017;127(8):3090–102. https://doi.org/10.1172/JCI91095.CrossRefPubMedPubMedCentral

21.

McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463–9. https://doi.org/10.1126/science.aaf1490.CrossRefPubMedPubMedCentral

22.

Lu X, Jiang L, Zhang L, et al. Immune signature-based subtypes of cervical squamous cell carcinoma tightly associated with human papillomavirus type 16 expression, molecular features, and clinical outcome. Neoplasia. 2019;21(6):591–601. https://doi.org/10.1016/j.neo.2019.04.003.CrossRefPubMedPubMedCentral

23.

Lu X, Meng J, Zhou Y, Jiang L, Yan F. MOVICS: an R package for multi-omics integration and visualization in cancer subtyping. Bioinformatics. 2021;36(22–23):5539–41. https://doi.org/10.1093/bioinformatics/btaa1018.CrossRefPubMed

24.

Hao D, He S, Harada K, et al. Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut. 2021;70(11):2055–65. https://doi.org/10.1136/gutjnl-2020-322707.CrossRefPubMed

25.

Lu X, Meng J, Su L, et al. Multi-omics consensus ensemble refines the classification of muscle-invasive bladder cancer with stratified prognosis, tumour microenvironment and distinct sensitivity to frontline therapies. Clin Transl Med. 2021. https://doi.org/10.1002/ctm2.601.CrossRefPubMedPubMedCentral

26.

Kiykim A, Ogulur I, Dursun E, et al. Abatacept as a long-term targeted therapy for LRBA deficiency. J Allergy Clin Immunol Pract. 2019;7(8):2790–800. https://doi.org/10.1016/j.jaip.2019.06.011.CrossRefPubMedPubMedCentral

27.

Sun SC. The non-canonical NF-kappaB pathway in immunity and inflammation. Nat Rev Immunol. 2017;17(9):545–58. https://doi.org/10.1038/nri.2017.52.CrossRefPubMedPubMedCentral

28.

Huang S, Wang J, Liu N, et al. A cross-tissue transcriptome association study identifies key genes in essential hypertension. Front Genet. 2023;14:1114174. https://doi.org/10.3389/fgene.2023.1114174.CrossRefPubMedPubMedCentral

29.

Huang X, Tang T, Zhang G, Liang T. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. Mol Cancer. 2021;20(1):50. https://doi.org/10.1186/s12943-021-01342-6.CrossRefPubMedPubMedCentral

30.

Chen S, Xie Y, Cai Y, et al. Multiomic analysis reveals comprehensive tumor heterogeneity and distinct immune subtypes in multifocal intrahepatic cholangiocarcinoma. Clin Cancer Res. 2022;28(9):1896–910. https://doi.org/10.1158/1078-0432.CCR-21-1157.CrossRefPubMed

31.

Nguyen CT, Caruso S, Maille P, et al. Immune profiling of combined hepatocellular- cholangiocarcinoma reveals distinct subtypes and activation of gene signatures predictive of response to immunotherapy. Clin Cancer Res. 2022;28(3):540–51. https://doi.org/10.1158/1078-0432.CCR-21-1219.CrossRefPubMed

32.

Job S, Rapoud D, Dos Santos A, et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology. 2020;72(3):965–81. https://doi.org/10.1002/hep.31092.CrossRefPubMed

33.

Raggi C, Taddei ML, Sacco E, et al. Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma. J Hepatol. 2021;74(6):1373–85. https://doi.org/10.1016/j.jhep.2020.12.031.CrossRefPubMed

34.

Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. https://doi.org/10.1126/science.aaa8172.CrossRefPubMed

35.

Gangoso E, Southgate B, Bradley L, et al. Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion. Cell. 2021;184(9):2454–70. https://doi.org/10.1016/j.cell.2021.03.023.CrossRefPubMedPubMedCentral

36.

Lehmann BD, Colaprico A, Silva TC, et al. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat Commun. 2021;12(1):6276. https://doi.org/10.1038/s41467-021-26502-6.CrossRefPubMedPubMedCentral

37.

Luo H, Li Y, Song H, et al. Role of EZH2-mediated epigenetic modification on vascular smooth muscle in cardiovascular diseases: a mini-review. Front Pharmacol. 2024;15:1416992. https://doi.org/10.3389/fphar.2024.1416992.CrossRefPubMedPubMedCentral

38.

Tazzari M, Bergamaschi L, De Vita A, et al. Molecular determinants of soft tissue sarcoma immunity: targets for immune intervention. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22147518.CrossRefPubMedPubMedCentral

39.

Wang E. Understanding genomic alterations in cancer genomes using an integrative network approach. Cancer Lett. 2013;340(2):261–9. https://doi.org/10.1016/j.canlet.2012.11.050.CrossRefPubMed

40.

Liang L, Fang JY, Xu J. Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy. Oncogene. 2016;35(12):1475–82. https://doi.org/10.1038/onc.2015.209.CrossRefPubMed

41.

Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 2019;10(4):751–65. https://doi.org/10.2103/jgo.2019.03.10.CrossRefPubMedPubMedCentral

42.

Zhang J, Wu J, Chen Y, Zhang W. Dlx5 promotes cancer progression through regulation of CCND1 in oral squamous cell carcinoma (OSCC). Biochem Cell Biol. 2021;99(4):424–34. https://doi.org/10.1139/bcb-2020-0523.CrossRefPubMed

43.

Huang Y, Yang Q, Zheng Y, et al. Activation of bivalent factor DLX5 cooperates with master regulator TP63 to promote squamous cell carcinoma. Nucleic Acids Res. 2021;49(16):9246–63. https://doi.org/10.1093/nar/gkab679.CrossRefPubMedPubMedCentral

44.

Zhang X, Bian H, Wei W, et al. DLX5 promotes osteosarcoma progression via activation of the NOTCH signaling pathway. Am J Cancer Res. 2021;11:3354–74.PubMedPubMedCentral

Title: New direction: identification of immunoinflammatory subtypes and potential therapeutic targets for cholangiocarcinoma
Authors: Zhixuan Chen
Honghu Song
Junrui Tang
Jiao Liu
Lina Xia
Publication date: 01-12-2024
Publisher: Springer US
Published in: Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-024-01628-3

Expression assays of selected lncRNAs in non-functioning pituitary adenomas

Open Access
Pituitary Adenoma
Research

Delineating the role of nuclear receptors in colorectal cancer, a focused review

Open Access
Colorectal Cancer
Review

Accuracy and influencing factors of Type B2 vessels in predicting the invasion depth of superficial esophageal squamous cell carcinoma under narrow-band imaging magnifying endoscopy

Open Access
Endoscopy
Research

Strobilurin X acts as an anticancer drug by inhibiting protein synthesis and suppressing mitochondrial respiratory chain activity

Open Access
Research

Pediatric cancer—pathology and microenvironment influence: a perspective into osteosarcoma and non-osteogenic mesenchymal malignant neoplasms

Open Access
Sarcoma
Perspective

Discovering the effect of combination of celecoxib and sorafenib on hepatocellular carcinoma

Open Access
Celecoxib
Analysis

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Keynote webinar | Spotlight on adolescent vaping

Live
Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET

Prof. Ann McNeill

Dr. Debbie Robson

Benji Horwell

Developed by: Springer Medicine

Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty in Geriatric Patients
On-demand webinar

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft

Prof. Barbara C. van Munster

Prof. Mirko Petrovic

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content